Mounjaro vs Zepbound: Same Drug, Different Coverage
They contain the identical molecule at identical doses. The difference is entirely in what each is approved to treat - and that single distinction can be the difference between a $25 copay and paying $1,100 a month.
Last updated: August 3, 2026
Quick Answer
Mounjaro and Zepbound are the same drug - tirzepatide - made by Eli Lilly, at the same doses, with the same mechanism and the same side effects. What differs is the FDA-approved indication:
- Mounjaro is approved for type 2 diabetes
- Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity
List prices are close - Mounjaro at $1,112.16 per fill and Zepbound at $1,086.37 - but the coverage outcomes are not. Mounjaro is generally more likely to be covered, because it is billed as diabetes treatment, while many plans exclude weight loss medications outright.
The practical rule: ask for the brand whose indication matches your actual diagnosis. Insurers authorise by product and indication, not by molecule.
Side-by-Side Comparison
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (identical) |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Chronic weight management; moderate-to-severe OSA with obesity |
| Mechanism | GLP-1 + GIP dual agonist | Identical |
| Doses available | 2.5-15 mg weekly | 2.5-15 mg weekly |
| Side effects | Same class profile | Same class profile |
| List price | $1,112.16 per fill | $1,086.37 per fill |
| Likelihood of coverage | Generally higher (diabetes) | More limited (weight loss exclusions) |
| Self-pay vials | Check current LillyDirect terms | $299-$449/month by dose |
Every row above the pricing lines is effectively identical. The medication is not better or worse under either name. Anyone telling you one works better than the other for weight loss is mistaken - they are the same tirzepatide.
Why Lilly Sells the Same Drug Twice
This looks like pure marketing, but there is real regulatory logic behind it.
- Separate trials, separate approvals. Getting a drug approved for type 2 diabetes requires different trials with different endpoints than getting it approved for chronic weight management. Each approval is its own regulatory application.
- Different labelling and dosing guidance. Prescribing information, warnings, and monitoring guidance differ between a diabetes population and a weight management population.
- Supply protection. Separating the brands helps prevent weight management demand from creating shortages for people who need the drug for diabetes - a genuine problem during the shortage years.
- Payer segmentation. Distinct products allow different pricing and contracting arrangements with insurers for different indications.
The same pattern exists across the class: semaglutide is sold as Ozempic for diabetes, Wegovy for weight management, and Rybelsus as an oral diabetes tablet. See our guide to every FDA-approved GLP-1 indication.
The Coverage Gap
This is where the identical-drug situation stops being a curiosity and starts costing people real money.
Mounjaro is generally more likely to be covered, but only for type 2 diabetes. Zepbound coverage is more limited because many insurance plans exclude weight loss medications as a category - a blanket exclusion that has nothing to do with the drug's effectiveness.
A situation that frustrates a lot of people: two patients, same weight, same drug, same dose. One has a type 2 diabetes diagnosis and gets Mounjaro covered with a modest copay. The other has obesity without diabetes, needs Zepbound, and gets denied outright. Same molecule, same pharmacy, wildly different outcome - purely because of which indication applies.
What You Cannot Do
To be direct about it: asking a prescriber to write Mounjaro when you do not have type 2 diabetes, in order to get coverage, is asking them to misrepresent your diagnosis to your insurer. That is insurance fraud, it puts your prescriber's licence at risk, and it can result in the claim being clawed back later. Reputable clinicians will decline, and you should not ask.
What You Can Do
- Get properly assessed for prediabetes or type 2 diabetes. If you genuinely meet diagnostic criteria and have not been tested, that is worth knowing regardless of medication.
- Use the sleep apnea indication. Zepbound is the only GLP-1 approved for moderate-to-severe OSA with obesity. If you have a sleep study showing AHI 15+, that is a much stronger claim than an obesity-only request. See our Zepbound for sleep apnea guide.
- Document comorbidities. Hypertension, dyslipidaemia, fatty liver, and osteoarthritis all strengthen a weight management prior authorisation.
- Appeal denials. First denials are common and frequently overturned.
- Check the Medicare GLP-1 Bridge if you are on Medicare - eligible Part D beneficiaries can access GLP-1s including Zepbound at a $50 copay. See our Bridge programme guide.
Which One Should You Ask For?
| Your Situation | Ask For |
|---|---|
| Type 2 diabetes, with or without obesity | Mounjaro |
| Obesity or overweight with a weight-related condition, no diabetes | Zepbound |
| Moderate-to-severe sleep apnea with obesity | Zepbound (OSA indication) |
| Type 2 diabetes and you also want weight loss | Mounjaro - you get both effects |
That last row is worth dwelling on. If you have type 2 diabetes, Mounjaro gives you the weight loss anyway - it is the same drug. You are not sacrificing weight loss by taking the diabetes-branded version. You are simply using the indication that your insurer is more likely to cover.
Real Costs and Self-Pay Options
| Route | Approximate Monthly Cost |
|---|---|
| Mounjaro list price | $1,112.16 per fill |
| Zepbound list price | $1,086.37 per fill |
| Zepbound self-pay vials (LillyDirect) | $299-$449 by dose |
| Medicare GLP-1 Bridge | $50 copay (eligible beneficiaries) |
| Compounded semaglutide programme | From $249 all-inclusive |
The most important cost lever for Zepbound is choosing single-dose vials over prefilled pens - roughly $299-$449 versus over $1,000 at list. Full detail in our Zepbound cost breakdown.
Denied for Both? From $249/month
If neither brand is covered and self-pay is out of reach, Coreage Rx provides physician-supervised compounded semaglutide from $249/month all-inclusive - consultation, medication, shipping, and dose management, with no insurance required.
Switching Between Them
Because the medication is identical, switching between Mounjaro and Zepbound is clinically straightforward - it is essentially a paperwork change rather than a treatment change.
- No re-titration needed. If you are stable on 10 mg Mounjaro, you move to 10 mg Zepbound. Same molecule, same dose, same exposure.
- No washout period. You continue your weekly schedule uninterrupted.
- Common triggers for switching: a new diabetes diagnosis, formulary changes at renewal, a new sleep apnea diagnosis making the Zepbound OSA indication available, or supply issues with one presentation.
- Watch the presentation. Pens and single-dose vials differ in administration even when the dose is the same - make sure you understand what you have been dispensed.
Your dosing schedule is unchanged either way. See our Mounjaro dosage chart and Zepbound dosage chart - which describe the same titration.
Frequently Asked Questions
Is Zepbound the same as Mounjaro?
Yes, in every clinically meaningful sense. Both contain tirzepatide, both are made by Eli Lilly, both come in the same 2.5-15 mg weekly doses, both work through dual GLP-1 and GIP receptor agonism, and both carry the same side effect profile. The difference is regulatory: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea.
Which is better for weight loss, Mounjaro or Zepbound?
Neither - they are the same drug and produce the same weight loss at the same dose. Anyone claiming one works better is mistaken. If you have type 2 diabetes and take Mounjaro, you get the full weight loss effect regardless of the branding on the box.
Which is cheaper, Mounjaro or Zepbound?
List prices are close - Mounjaro at $1,112.16 per fill and Zepbound at $1,086.37 - so the real difference is coverage, not sticker price. Mounjaro is generally more likely to be covered because it is billed as diabetes treatment, while many plans exclude weight loss drugs entirely. On self-pay, Zepbound single-dose vials through LillyDirect run $299-$449 per month by dose.
Can I ask my doctor to prescribe Mounjaro instead so insurance covers it?
Not unless you actually have type 2 diabetes. Asking a prescriber to write a diabetes-indicated drug when you do not have diabetes means misrepresenting your diagnosis to your insurer - that is insurance fraud, it puts your prescriber's licence at risk, and claims can be clawed back later. What you can legitimately do is get properly assessed for prediabetes or diabetes, pursue the Zepbound sleep apnea indication if you qualify, document comorbidities, and appeal denials.
Do Mounjaro and Zepbound have different side effects?
No. Same molecule, same dose, same side effect profile - nausea, vomiting, diarrhoea, constipation, and reflux, concentrated during dose escalation. Both carry the boxed warning for thyroid C-cell tumours and the same warnings regarding pancreatitis, gallbladder disease, and hypoglycaemia when combined with insulin or sulfonylureas.
Can I switch from Mounjaro to Zepbound without re-titrating?
Clinically it is a direct switch at the same dose, since the medication is identical - if you are stable on 10 mg Mounjaro you move to 10 mg Zepbound with no washout. That said, your prescriber should manage the change and confirm the presentation you receive, since pens and single-dose vials differ in administration even at the same dose.
Is Mounjaro approved for sleep apnea?
No. The obstructive sleep apnea approval belongs to Zepbound specifically, for moderate-to-severe OSA in adults with obesity. Mounjaro contains the same tirzepatide but is approved only for type 2 diabetes. Since insurers authorise by product and indication rather than by molecule, this matters for coverage - you would need Zepbound to claim the OSA indication.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical, legal, or insurance advice. Mounjaro and Zepbound are prescription medications that should only be used under the supervision of a qualified healthcare provider. Prescribing decisions, including which product is appropriate for your diagnosis, belong to your prescriber. Nothing in this article should be interpreted as encouragement to misrepresent a diagnosis to an insurer. Pricing and coverage reflect publicly available information at the time of writing and change frequently. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.